Skyrizi Dosage: Strengths, Forms, When to Use, and More

Skyrizi is one of those medications that sounds simple until you look at the dosing schedule and realize it has entered the chat with multiple forms, multiple strengths, and different plans depending on what condition is being treated. For plaque psoriasis and psoriatic arthritis, the routine is fairly streamlined. For Crohn’s disease and ulcerative colitis, things get more dramatic: there is an IV induction phase first, then a switch to under-the-skin maintenance doses. In other words, this is not a “one-size-fits-all” prescription with a cute little calendar reminder and a pat on the back.

If you are researching Skyrizi dosage, you are probably trying to answer one of a few practical questions: What strength does it come in? How often is it taken? Which form is used for psoriasis versus IBD? And when do doctors actually use it? This guide breaks all of that down in plain English. It is written for readers who want the details without needing a decoder ring for medical jargon. Still, the golden rule remains the same: the official prescribing instructions from your clinician always beat the internet, including this article.

What Is Skyrizi, Exactly?

Skyrizi is the brand name for risankizumab-rzaa, a biologic medication that targets interleukin-23, often shortened to IL-23. That protein plays a major role in inflammation, which is why Skyrizi is used for immune-mediated conditions rather than everyday aches, random rashes, or that one Tuesday when your body feels personally offended by pollen.

In the United States, Skyrizi is approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, adults with active psoriatic arthritis, and adults with moderately to severely active Crohn’s disease or ulcerative colitis. That approved-use list matters because Skyrizi dosing changes by condition. The same drug name appears on the box, but the schedule and form are not interchangeable across every diagnosis.

Skyrizi Dosage at a Glance

Plaque Psoriasis Dosage

For adults with moderate to severe plaque psoriasis, the recommended Skyrizi dosage is 150 mg by subcutaneous injection at Week 0, Week 4, and then every 12 weeks thereafter. That long maintenance interval is one reason the drug gets attention: after the loading phase, the calendar becomes a lot less crowded.

Psoriatic Arthritis Dosage

For adults with active psoriatic arthritis, the dosage is also 150 mg by subcutaneous injection at Week 0, Week 4, and then every 12 weeks. In psoriatic arthritis, Skyrizi may be used alone or with certain non-biologic disease-modifying antirheumatic drugs, depending on the treatment plan.

Crohn’s Disease Dosage

For moderately to severely active Crohn’s disease, Skyrizi follows a two-step approach. First comes induction: 600 mg by IV infusion at Week 0, Week 4, and Week 8. After that comes maintenance: 180 mg or 360 mg by subcutaneous injection starting at Week 12 and then every 8 weeks. The goal is to use the lowest effective maintenance dose that keeps the therapeutic response going.

Ulcerative Colitis Dosage

For moderately to severely active ulcerative colitis, the pattern is similar but the IV induction dose is higher. Induction is 1,200 mg by IV infusion at Week 0, Week 4, and Week 8. Maintenance is 180 mg or 360 mg by subcutaneous injection at Week 12 and every 8 weeks thereafter. Again, clinicians aim for the lowest effective maintenance dose.

Skyrizi Strengths and Forms

This is where Skyrizi can feel like it is trying to win an award for product variety. The medication comes in several forms because different diseases, different stages of treatment, and different delivery methods require different setups.

• 150 mg/mL prefilled pen
• 150 mg/mL prefilled syringe
• 180 mg/1.2 mL prefilled syringe
• 180 mg/1.2 mL prefilled cartridge for use with an on-body injector
• 360 mg/2.4 mL prefilled cartridge for use with an on-body injector
• 600 mg/10 mL single-dose vial for IV infusion
• A labeled 90 mg/mL prefilled syringe configuration used in certain administration setups

For plaque psoriasis and psoriatic arthritis, the most familiar forms are the 150 mg pen and 150 mg prefilled syringe. For Crohn’s disease and ulcerative colitis, the picture is more mixed. The IV vial is used during induction, while maintenance may involve a prefilled syringe or a prefilled cartridge used with an on-body injector. That means some patients start in an infusion setting and later transition to at-home subcutaneous dosing after proper training.

The big takeaway is simple: if two people both say they are “on Skyrizi,” they may still be using very different products, at very different doses, on very different schedules. The disease being treated decides the route, strength, and timing.

When Is Skyrizi Used?

Skyrizi is generally used when a person has a condition that is active enough to need more than basic first-line measures. In plaque psoriasis, that usually means disease severe enough that topical creams alone are not doing the job, or the person is considered a candidate for systemic therapy or phototherapy. In psoriatic arthritis, it is used when joint inflammation and related symptoms need a biologic approach rather than a casual shrug and a heating pad.

In Crohn’s disease and ulcerative colitis, Skyrizi is used for moderate to severe disease, and it fits into the broader category of advanced therapy. Modern gastroenterology guidance increasingly treats these biologic options as important tools for controlling inflammation and maintaining remission, not as some mythical last resort that must wait behind every other medicine on Earth.

That said, “when to use” is not the same as “when to self-prescribe.” Skyrizi is not an as-needed medication, not a rescue drug for occasional symptoms, and definitely not something to dose by personal improvisation. It is a scheduled biologic therapy chosen according to diagnosis, disease severity, prior treatment history, and safety monitoring.

Why the Dosage Changes by Condition

One of the most important things readers miss when comparing Skyrizi dosage is that psoriasis and psoriatic arthritis use one dosing rhythm, while inflammatory bowel disease uses another. That is not a typo, and it is not your pharmacist trying to keep life exciting. It reflects how the drug was studied and approved for different diseases.

For psoriasis and psoriatic arthritis, the dosing schedule is relatively simple: a starting dose, a second dose four weeks later, then maintenance every 12 weeks. For Crohn’s disease and ulcerative colitis, treatment begins with IV induction doses before switching to subcutaneous maintenance every 8 weeks. In practical terms, the IBD schedule asks for more front-end structure, while the psoriasis schedule is lighter after the loading phase.

This is also why it is risky to compare your dose to someone else’s without context. A friend using Skyrizi for plaque psoriasis is not a useful reference point if your doctor is prescribing it for ulcerative colitis. Same brand, different playbook.

How Skyrizi Is Given in Real Life

In real-world use, Skyrizi administration is part medication, part routine, part logistics. Subcutaneous doses are typically given in the thighs, abdomen, or upper outer arms, though upper-arm administration may need to be done by a caregiver or healthcare professional. Patients are instructed not to inject into skin that is tender, bruised, red, hardened, scarred, or actively affected by lesions.

The medication also needs a little patience before use. Depending on the device, it is typically allowed to warm to room temperature outside direct sunlight for a set period before injection. That means Skyrizi is not the kind of medicine you grab from the fridge and slam into your schedule in 14 seconds flat. There is a process, and your future self will appreciate following it.

For Crohn’s disease and ulcerative colitis, some patients begin with infusions in a clinical setting, then move to home maintenance using a syringe or on-body injector after training. That transition can feel intimidating at first, but it is also the point where many people feel the treatment becomes more manageable because it no longer revolves around infusion appointments alone.

What If You Miss a Dose?

If a Skyrizi dose is missed, the general instruction is to take it as soon as possible and then resume the regular dosing schedule. That sounds straightforward, and it usually is, but biologic schedules are not the best place for guesswork. If the timing is confusing, especially with infusion-based induction or long maintenance intervals, the safest move is to check with the prescribing clinician or specialty pharmacy.

What you should not do is double up on doses or create your own “catch-up” plan because the calendar got messy. Skyrizi works best as a structured therapy, not as freestyle medication choreography.

Safety Checks Before Starting Skyrizi

Before Skyrizi begins, several safety steps matter. Patients should be evaluated for tuberculosis before treatment starts. If there is an active infection, treatment is generally delayed until the infection resolves or is adequately treated. Patients with chronic or recurrent infections may need closer consideration before using the drug.

Vaccination status also matters. Patients are advised to complete age-appropriate vaccinations before starting therapy, and live vaccines are generally avoided during treatment. For Crohn’s disease and ulcerative colitis, the U.S. prescribing information also recommends checking liver enzymes and bilirubin at baseline and during induction, at least through the first 12 weeks, because drug-induced liver injury has been reported in IBD treatment.

That is one reason Skyrizi dosing is more than a number on a package. Proper use includes timing, route, monitoring, and the right safety screening before the first dose even arrives.

Common Side Effects to Know

Like many biologics, Skyrizi can increase the risk of infections. Common side effects vary somewhat by condition and treatment phase, but they may include upper respiratory infections, headache, fatigue, injection-site reactions, arthralgia, abdominal pain, fever, rash, anemia, back pain, or fungal skin infections. Not every patient gets these side effects, and many are mild, but they are worth recognizing early rather than pretending every new symptom is just “probably the weather.”

Serious hypersensitivity reactions can also occur, though they are less common. Any signs of a serious allergic reaction, ongoing infection, or possible liver trouble should be taken seriously and reported promptly.

Frequently Asked Questions About Skyrizi Dosage

Can Skyrizi be taken more often to work faster?

No. Skyrizi should be taken exactly as prescribed. More frequent dosing is not a do-it-yourself upgrade.

Is the 150 mg dose used for every condition?

No. The 150 mg schedule is used for plaque psoriasis and psoriatic arthritis. Crohn’s disease and ulcerative colitis use different induction and maintenance doses.

Can patients inject Skyrizi at home?

Many can, depending on the form and the condition being treated. Home injection is typically done only after proper training.

How long does Skyrizi take to work?

Some patients notice improvement within weeks, but full benefit may take longer. That timeline varies by disease and by individual response, so it is best not to panic if the first dose does not produce fireworks.

Patient Experience: What Living on a Skyrizi Schedule Often Feels Like

From a patient-experience perspective, Skyrizi dosing often feels less overwhelming once the schedule is mapped clearly. The biggest mental shift is realizing that this is not a daily medication. People who start Skyrizi for psoriasis or psoriatic arthritis often describe the first part of treatment as learning three anchor points: the first dose, the Week 4 dose, and then the much more relaxed every-12-week rhythm. Once that pattern clicks, the drug can feel surprisingly low-maintenance compared with treatments that demand constant weekly attention.

For someone with Crohn’s disease or ulcerative colitis, the experience is usually different at first. The IV induction phase makes treatment feel more medical, more visible, and more tied to appointments. Week 0, Week 4, and Week 8 can become major calendar events. Then maintenance begins, and the experience often changes again. The treatment starts to feel more like a routine that can be planned around real life instead of the other way around. That transition matters emotionally as much as practically. A therapy can feel much more manageable once it stops acting like it owns your entire month.

There is also the learning curve with devices. Some people are comfortable with injections right away. Others need a few rounds of training, note-taking, deep breathing, and a pep talk from a nurse, a partner, or their own determined inner narrator. Warming the medication, choosing an injection site, rotating locations, and keeping supplies organized can make the process feel less intimidating. It is not glamorous, but neither is losing a dose because it stayed buried behind yogurt in the fridge.

Another very real part of the experience is the non-medication side of medication. Insurance approvals, specialty pharmacy coordination, infusion scheduling, refill timing, travel planning, and reminder systems all become part of the dosage story. A person may know the exact milligrams perfectly and still struggle more with paperwork than with the medicine itself. That is normal. In fact, for many patients, “managing Skyrizi dosage” means managing the whole support system around it: appointments, lab checks, vaccine timing, infection precautions, and staying in touch with the care team when something feels off.

The best practical mindset is not to treat Skyrizi like a magic switch or a mysterious biotech puzzle. It is a structured therapy with a clear plan. The more clearly that plan is understood, the less stressful the experience tends to feel. Patients usually do best when they know what form they are using, why their schedule looks the way it does, what to do about a missed dose, and which symptoms deserve a call to the doctor. That kind of clarity does not make chronic illness fun, obviously, but it does make treatment feel more doableand “doable” is often a very big win.

Final Takeaway

Skyrizi dosage depends heavily on the condition being treated. For plaque psoriasis and psoriatic arthritis, the standard adult schedule is 150 mg at Week 0, Week 4, and then every 12 weeks. For Crohn’s disease and ulcerative colitis, treatment begins with IV induction and then moves to 180 mg or 360 mg subcutaneous maintenance every 8 weeks. The medication also comes in several forms, including pens, syringes, cartridges used with an on-body injector, and IV vials.

The smartest way to think about Skyrizi is this: same brand name, very condition-specific dosing. If you understand that one principle, the rest of the schedule starts making a lot more sense. And in the world of biologics, making sense is half the battle.